Epocrates, a popular provider of mobile drug reference tools, has re-filed for an estimated $75 million initial public offering, that will see its shares traded on NASDAQ under the symbol EPOC. Epocrates plans to use proceeds from the IPO for working capital, research and development, sales and marketing and capital expenditures, according to a filing with the SEC. Epocrates filed similar $75...
